These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29732965)

  • 1. Otilonium Bromide: A Drug with a Complex Mechanism of Action.
    Evangelista S; Traini C; Vannucchi MG
    Curr Pharm Des; 2018; 24(16):1772-1779. PubMed ID: 29732965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.
    Rychter J; Espín F; Gallego D; Vergara P; Jiménez M; Clavé P
    Therap Adv Gastroenterol; 2014 Jul; 7(4):156-66. PubMed ID: 25057296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of otilonium bromide on contractile patterns in the human sigmoid colon.
    Gallego D; Aulí M; Aleu J; Martínez E; Rofes L; Martí-Ragué J; Jiménez M; Clavé P
    Neurogastroenterol Motil; 2010 Jun; 22(6):e180-91. PubMed ID: 20367799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Otilonium bromide inhibits calcium entry through L-type calcium channels in human intestinal smooth muscle.
    Strege PR; Evangelista S; Lyford GL; Sarr MG; Farrugia G
    Neurogastroenterol Motil; 2004 Apr; 16(2):167-73. PubMed ID: 15086870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
    Clavé P; Acalovschi M; Triantafillidis JK; Uspensky YP; Kalayci C; Shee V; Tack J;
    Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Otilonium bromide: a selective spasmolytic for the gastrointestinal tract.
    Evangelista S
    J Int Med Res; 1999; 27(5):207-22. PubMed ID: 10689627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimuscarinic, calcium channel blocker and tachykinin NK2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea-pig colon.
    Santicioli P; Zagorodnyuk V; Renzetti AR; Maggi CA
    Naunyn Schmiedebergs Arch Pharmacol; 1999 May; 359(5):420-7. PubMed ID: 10498293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome.
    Evangelista S
    Curr Pharm Des; 2004; 10(28):3561-8. PubMed ID: 15579053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of antispasmodics in the treatment of irritable bowel syndrome.
    Annaházi A; Róka R; Rosztóczy A; Wittmann T
    World J Gastroenterol; 2014 May; 20(20):6031-43. PubMed ID: 24876726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of action of otilonium bromide (OB) in human cultured smooth muscle cells and rat colonic strips.
    Martínez-Cutillas M; Gil V; Gallego D; Mañé N; Martín MT; Jiménez M
    Neurogastroenterol Motil; 2013 Dec; 25(12):e803-12. PubMed ID: 23941257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress.
    Traini C; Evangelista S; Girod V; Faussone-Pellegrini MS; Vannucchi MG
    J Cell Mol Med; 2017 Apr; 21(4):735-745. PubMed ID: 27866394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.
    Lindqvist S; Hernon J; Sharp P; Johns N; Addison S; Watson M; Tighe R; Greer S; Mackay J; Rhodes M; Lewis M; Stebbings W; Speakman C; Evangelista S; Johnson I; Williams M
    Br J Pharmacol; 2002 Dec; 137(7):1134-42. PubMed ID: 12429587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Otilonium Bromide treatment prevents nitrergic functional and morphological changes caused by chronic stress in the distal colon of a rat IBS model.
    Traini C; Idrizaj E; Garella R; Faussone-Pellegrini MS; Baccari MC; Vannucchi MG
    J Cell Mol Med; 2021 Jul; 25(14):6988-7000. PubMed ID: 34109728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-type Ca(2+) channel modulation by otilonium bromide.
    Strege PR; Sha L; Beyder A; Bernard CE; Perez-Reyes E; Evangelista S; Gibbons SJ; Szurszewski JH; Farrugia G
    Am J Physiol Gastrointest Liver Physiol; 2010 May; 298(5):G706-13. PubMed ID: 20203058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irritable bowel syndrome: focus on otilonium bromide.
    Boeckxstaens G; Clavé P; Corazziari ES; Tack J
    Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):131-7. PubMed ID: 24417261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Otilonium bromide inhibits muscle contractions via L-type calcium channels in the rat colon.
    Martin MT; Hove-Madsen L; Jimenez M
    Neurogastroenterol Motil; 2004 Apr; 16(2):175-83. PubMed ID: 15086871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological studies on otilonium bromide.
    Giachetti A
    Ital J Gastroenterol; 1991 Nov; 23(8 Suppl 1):56-9. PubMed ID: 1661629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irritable bowel syndrome.
    Spinelli A
    Clin Drug Investig; 2007; 27(1):15-33. PubMed ID: 17177577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic treatment with otilonium bromide induces changes in L-type Ca²⁺ channel, tachykinins, and nitric oxide synthase expression in rat colon muscle coat.
    Traini C; Cipriani G; Evangelista S; Santicioli P; Faussone-Pellegrini MS; Vannucchi MG
    Neurogastroenterol Motil; 2013 Nov; 25(11):e728-39. PubMed ID: 23901937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.
    Forte E; Pizzoferrato M; Lopetuso L; Scaldaferri F
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):25-37. PubMed ID: 22338545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.